AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

Allergan

Status and phase: Completed; Phase 3

Conditions: Conjunctivitis, Allergic

Treatments: Drug: AGN-229666

Study type: Interventional

Funder types: Industry

Identifiers

NCT02082262

229666-005

Details and patient eligibility

About

This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.

Enrollment: 140 patients

Sex: All

Ages: 10+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Japanese patients living in Japan with allergic conjunctivitis with itching and redness
• Able and willing to discontinue wearing any contact lenses during the study period.

Exclusion criteria

• Eye surgical intervention and/or a history of refractive surgery within 6 months
• History of retinal detachment, diabetic retinopathy, or progressive retinal disease
• Presence of active eye infection (bacterial, viral, or fungal)
• History of an eye herpetic infection
• Use of corticosteroids within 6 months or anticipated use during the study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

140 participants in 1 patient group

AGN-229666

Experimental group

Description:

One to two drops of AGN-229666 twice daily in each eye for 10 weeks.

Treatment:

Drug: AGN-229666